CORT
CORCEPT THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$87.75
−18.38%Year over year
Reported trailing growth
- Revenue
- +16.0%
- EBITDA
- -75.0%
- EBIT
- -93.7%
- EPS
- -58.7%
- Free cash flow
- -40.7%
- Operating cash flow
- -39.8%
Forward estimates
Based on analyst estimates
- Revenue
- +97.8%
- EBITDA
- +2073.0%
- EPS
- +808.0%
Three-year CAGR
- Revenue
- +23.7%
- EBITDA
- -17.0%
- EBIT
- -26.5%
- Net income
- -0.6%
- EPS
- +0.0%
- Free cash flow
- +5.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026